Coverage
-
February 21, 2017
A newly disclosed warning letter to Pfizer is setting off a chain reaction that will likely delay a generic version of Teva's blockbuster Copaxone, one of the world's best-selling drugs. Here's a look at the remarkable development and other U.S. Food and Drug Administration warnings announced in recent days.
1 other articles on this case.
View all »